I, too, was hoping for a reverse split into RCPI if that was possible. However, that would carry with it the burdensome debt which caused RCPI to go the Chapter 7 route. It looks like Akers Bio will become the financial source that MYMD Pharma needs, to do the phase 2 studies it recently listed.
Akers has agreed to loan MYMD UP TO 3 million dollars, probably funding for MYMD until they merge. In the meantime Akers is doing a private placement of nearly 10 million shares, netting 18 million dollars. The placement includes warrents which will add additional funding over the next 5 years. This will probably be detailed in tomorrow's report at 4;15 Eastern.
